BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1419 related articles for article (PubMed ID: 29132393)

  • 21. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
    Anderson AG; Gaffy CB; Weseli JR; Gorres KL
    Viruses; 2019 May; 11(5):. PubMed ID: 31108875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epstein-Barr Virus Hijacks DNA Damage Response Transducers to Orchestrate Its Life Cycle.
    Hau PM; Tsao SW
    Viruses; 2017 Nov; 9(11):. PubMed ID: 29144413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain.
    Trivedi P; Spinsanti P; Cuomo L; Volpe M; Takada K; Frati L; Faggioni A
    J Virol; 2001 May; 75(10):4929-35. PubMed ID: 11312367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.
    Majerciak V; Yang W; Zheng J; Zhu J; Zheng ZM
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BHLF1 Locus of Epstein-Barr Virus Contributes to Viral Latency and B-Cell Immortalization.
    Yetming KD; Lupey-Green LN; Biryukov S; Hughes DJ; Marendy EM; Miranda JL; Sample JT
    J Virol; 2020 Aug; 94(17):. PubMed ID: 32581094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.
    Kim H; Choi H; Lee SK
    J Virol; 2016 Feb; 90(3):1359-68. PubMed ID: 26581978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression of the EBV lytic switch protein in Burkitt lymphoma cells.
    Reinhart NM; Akinyemi IA; Frey TR; Xu H; Agudelo C; Brathwaite J; Burton EM; Burgula S; McIntosh MT; Bhaduri-McIntosh S
    Virology; 2022 Jan; 566():136-142. PubMed ID: 34922257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon regulatory factor 8 regulates caspase-1 expression to facilitate Epstein-Barr virus reactivation in response to B cell receptor stimulation and chemical induction.
    Lv DW; Zhang K; Li R
    PLoS Pathog; 2018 Jan; 14(1):e1006868. PubMed ID: 29357389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivation of Epstein-Barr virus from latency.
    Amon W; Farrell PJ
    Rev Med Virol; 2005; 15(3):149-56. PubMed ID: 15546128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
    Jung YJ; Choi H; Kim H; Lee SK
    J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latent and lytic Epstein-Barr virus replication strategies.
    Tsurumi T; Fujita M; Kudoh A
    Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Rta in B Lymphocytes during Epstein-Barr Virus Latency.
    Hwang SP; Huang LC; Wang WH; Lin MH; Kuo CW; Huang HH; Chang LK
    J Mol Biol; 2020 Sep; 432(19):5227-5243. PubMed ID: 32710985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells.
    Ansari MA; Singh VV; Dutta S; Veettil MV; Dutta D; Chikoti L; Lu J; Everly D; Chandran B
    J Virol; 2013 Aug; 87(15):8606-23. PubMed ID: 23720728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
    Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
    J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
    Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
    PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
    Church TM; Verma D; Thompson J; Swaminathan S
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 71.